Moss Adams Wealth Advisors LLC Has $967,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Moss Adams Wealth Advisors LLC raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 212.7% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 1,357 shares of the biopharmaceutical company’s stock after purchasing an additional 923 shares during the period. Moss Adams Wealth Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $967,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of REGN. Monarch Capital Management Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 106.0% during the fourth quarter. Monarch Capital Management Inc. now owns 1,067 shares of the biopharmaceutical company’s stock worth $760,000 after acquiring an additional 549 shares in the last quarter. HB Wealth Management LLC raised its stake in shares of Regeneron Pharmaceuticals by 8.2% during the 4th quarter. HB Wealth Management LLC now owns 2,129 shares of the biopharmaceutical company’s stock worth $1,516,000 after purchasing an additional 161 shares in the last quarter. Trust Co. of Vermont raised its stake in shares of Regeneron Pharmaceuticals by 199.4% during the 4th quarter. Trust Co. of Vermont now owns 470 shares of the biopharmaceutical company’s stock worth $335,000 after purchasing an additional 313 shares in the last quarter. Integrated Investment Consultants LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 6.8% during the 4th quarter. Integrated Investment Consultants LLC now owns 609 shares of the biopharmaceutical company’s stock valued at $434,000 after buying an additional 39 shares during the last quarter. Finally, B & T Capital Management DBA Alpha Capital Management grew its stake in shares of Regeneron Pharmaceuticals by 154.8% in the 4th quarter. B & T Capital Management DBA Alpha Capital Management now owns 3,147 shares of the biopharmaceutical company’s stock valued at $2,242,000 after buying an additional 1,912 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Down 1.7 %

NASDAQ REGN opened at $681.58 on Friday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $666.25 and a twelve month high of $1,211.20. The stock has a market cap of $74.90 billion, a PE ratio of 16.87, a PEG ratio of 1.60 and a beta of 0.10. The firm has a 50-day simple moving average of $738.60 and a 200 day simple moving average of $949.99. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28.

Analysts Set New Price Targets

Several equities analysts recently weighed in on REGN shares. Leerink Partners reaffirmed a “market perform” rating and set a $1,077.00 price objective (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. Bank of America reaffirmed an “underperform” rating and issued a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Morgan Stanley reduced their price target on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Finally, Barclays lowered their price objective on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. One analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $1,015.38.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.